The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).
Stephen R. D. Johnston
Disclosure not yet available
Mark Basik
Disclosure not yet available
Roberto Hegg
Disclosure not yet available
Wirote Lausoontornsiri
Disclosure not yet available
Lukasz Grzeda
Disclosure not yet available
Mark Clemons
Disclosure not yet available
Lydia Mary Dreosti
Disclosure not yet available
Serban Ghiorghiu
Disclosure not yet available
Helen Mann
Disclosure not yet available
Donal Landers
Disclosure not yet available
Mary Stuart
Disclosure not yet available
Massimo Cristofanilli
Disclosure not yet available